Study Name: Ralinepag 301

Study Objective: A Phase 3, randomized, double-blind, placebo-controlled study to

evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background oral therapy in subjects with World

Health Organization (WHO) Group 1 pulmonary hypertension (ADVANCE Outcomes)

Key Inclusion Criteria:

• Primary diagnosis of symptomatic PAH, IPAH, HPAH
• WHO/NYHA FC II to IV symptoms
• RHC w/i 3 yrs or at screening

Key Exclusion Criteria:

3 or more of following:

•  BMI ≥30
• DM
• HTN
• CAD
• Chronic AF

2. Evidence of > mild lung disease on PFT w/i 6M

3. Evidence of thromboembolic disease

4. Severe chronic liver disease